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Summary
Objective: To assess immunogenicity, antibody persistence, immune memory, and reactogenicity
of a novel heptavalent DTPw—HBV/Hib—MenAC (diphtheria, tetanus, whole cell pertussis—hepa-
titis B virus/Haemophilus influenzae type b—Neisseria meningitidis serogroups A and C) vaccine.
Design: This was an open, randomized study in the Philippines, with DTPw—HBV/Hib—MenAC
administered at 6, 10, and 14 weeks of age. Three different polysaccharide contents of the
conjugate vaccine components were assessed with conjugated PRP (polyribosylribitol phosphate),
MenA, and MenC polysaccharides at the following doses: 2.5 mg of each, 5 mg of each, or 2.5 mg of
PRP and 5 mg each of MenA and MenC. Controls received licensed DTPw—HBV and Hib or DTPw—
HBV/Hib and MenC conjugate vaccines separately. Immune memory was evaluated via plain
polysaccharide challenge administered to half of the subjects at 10 months of age.
Results: After primary vaccination, at least 97.7% of DTPw—HBV/Hib—MenAC recipients had serum
bactericidal antibody (SBA)—MenA and SBA—MenC titers 1:8, and at least 99% had anti-PRP§ Data from primary and challenge phases of this study were presented as posters at the International Pathogenic Neisseria Conference,
Milwaukee, USA, 5—10 September, 2004.
* Corresponding author. Tel.: +32 2 656 9136; fax: +32 2 656 8044.
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1201-9712/$32.00 # 2008 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
doi:10.1016/j.ijid.2007.08.007
DTP—wHBV/Hib—MenAC vaccines: randomized dose-ranging trial 279
antibody concentrations 0.15 mg/ml. Immune responses to DTPw—HBV components were not
impaired by the lowest dose of Hib—MenAC vaccine. Plain polysaccharide challenge induced marked
increases in Hib, MenA, and MenC antibodies in primed subjects, indicative of immune memory. All of
the experimental vaccines were well tolerated.
Conclusion: The lowest dose of DTPw—HBV/Hib—MenAC polysaccharide conjugate vaccine was well
tolerated, immunogenic, had good persistence of antibodies, and demonstrated immune memory, and
consequently was selected for further development.
# 2008 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.Introduction
Neisseria meningitidis causes endemic and epidemic menin-
gococcal disease worldwide with at least 30 000 deaths esti-
mated to occur each year.1 This figure does not consider the
numbers who die in rural areas of Africa and Asia before
reaching medical facilities. Mortality in some regions may
reach 15%evenwith treatment,with amuch higher proportion
of victims left with long-term sequelae including limb loss
and neurological deficit.1,2 Children under 5 years of age are
most often affected by endemic disease, while infants under
3months of age seemtobeprotected bymaternal antibodies.2
Although outbreaks due to serogroup C (MenC) and more
recently W-135 and serogroup X have been reported in Africa
and Asia, serogroup A (MenA) accounts for most meningo-
coccal epidemics and particularly affects countries within
the ‘meningitis belt’ of Africa.3—8 In Asia, serogroup A has
been responsible for three pandemics since the 1960s: the
first began in China in the mid 1960s, the second one started
in China and Nepal in the 1980s, extending to India, Bhutan,
Saudi Arabia, and Yemen, and the third one began in China in
1994 and moved to Mongolia, Russia, and Africa.9,10 In addi-
tion to these pandemics, epidemics have affected Mongolia
(1973—74) and Vietnam (1977). More recently, Taiwan
reported a re-emergence of MenA cases in 2001; MenA out-
breaks also occurred in India and the Philippines in 2005.9—11
Endemic disease rates in Africa may be as high as 20/
100 000, but during epidemics may reach more than 1000/
100 000.1,2,6 To place this rate in perspective, an overall
disease incidence rate of approximately 10/100 000 was
observed during the 1999 MenC epidemic in England and
Wales prior to the introduction of MenC conjugate vaccines.12
Meningococcal polysaccharide vaccines have been avail-
able since the 1980s and are effective in preventing disease.
However these vaccines do not provide long-term protection,
their effect on carriage is minimal, and their use is therefore
restricted to epidemic situations.1,2 Except for serogroup A
polysaccharide that induces an immune response in infants
under 1 year of age with some evidence of efficacy, menin-
gococcal polysaccharide vaccines are poorly immunogenic in
young children under 2 years of age. Furthermore, adminis-
tration of the MenC polysaccharide is found to cause hypor-
esponsiveness to subsequent doses of MenC vaccine.13
The availability of MenC conjugate vaccines has fundamen-
tally altered the epidemiology of MenC disease in countries
where vaccination has been widely implemented.12,14 The
developmentofaneffectiveMenAconjugatevaccine for infant
immunization would enlarge endemic and epidemic invasive
meningococcal disease control even further. TheWorld Health
Organization (WHO) Expanded Program on Immunization (EPI)
currently recommends routine vaccination against diphtheria,tetanus, pertussis, hepatitis B virus (HBV), polio, and Haemo-
philus influenzae type b (Hib) for all infants.15 Whole-cell
pertussis vaccines are most commonly used in less industria-
lizedcountriesmostly becauseof lowercost compared tomore
recent acellular pertussis vaccines. In endemic areas where
poliomyelitis has not been eradicated yet, WHO recommends
the use of oral polio vaccine (OPV).16 Combined diphtheria—
tetanus—whole-cell pertussis—hepatitis B (DTPw—HBV) and
DTPw—HBV/Hibvaccinesarenowwidelyused,andtheir cover-
age is increasing.TheadditionofMenAandMenCconjugates to
these existing vaccines will promote rapid uptake and high
coverage of the new components, while minimizing cost and
logistical problems in vaccine delivery.
This study evaluated three novel heptavalent DTPw—
HBV/Hib—MenAC combination vaccines that differed in
the dose of the Hib—MenAC conjugate component, for use
in a three-dose primary schedule during the first year of life.
Methods
Study design and subjects
The study was an open, randomized study in the Philippines,
conducted in two phases: primary vaccination (study
number: 759346/001) and polysaccharide challenge (study
number: 759346/002). The study protocols (NCT00317174)
were reviewed and approved by the relevant ethics commit-
tee and were conducted according to Good Clinical Practice
Guidelines and the Declaration of Helsinki. Written informed
consent was obtained from the parent/guardian of every
child prior to enrolment in the study.
Healthy infants aged between 6 and 10 weeks at the time
of the first vaccination were eligible for inclusion. Subjects
were excluded if they had a major congenital defect or
serious chronic illness, any confirmed or suspected immuno-
suppressive or immunodeficient condition, evidence of pre-
vious diphtheria, tetanus, pertussis, hepatitis B, Hib, MenA
and/or MenC vaccination or disease, any history of allergic
reactions to any vaccine component, receipt of any investi-
gational or non-registered drug or vaccine within 30 days
before or during the study, or receipt of immunosuppressive
or immunoglobulin therapy or blood products before enrol-
ment or during the study. Subjects were also excluded if they
had received hepatitis B or Bacille Calmette—Gue´rin vaccine
after the first two weeks of life.
In the primary phase of the study, 525 eligible infants were
randomized to one of five groups (1:1:1:1:1). Three groups
evaluated different doses of the novel heptavalent vaccine:
group 2.5/2.5 received DTPw—HBV/Hib—MenAC containing
2.5 mg each of conjugated PRP (polyribosylribitol phos-
phate), MenA, and MenC polysaccharides, group 2.5/5
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PRP and 5 mg each of conjugated MenA and MenC polysac-
charides, and group 5/5 received DTPw—HBV/Hib—MenAC
containing 5 mg each of conjugated PRP, MenA, and MenC
polysaccharides. Two control groups received licensed vac-
cines: group DTPw—HBV + Hib received separate administra-
tion of TritanrixTM-HepB and HiberixTM and group DTPw—
HBV/Hib + MenC received separate administration of Tritan-
rixTM-HepB/HiberixTM and MeningitecTM. All vaccines were
administered intramuscularly at 6, 10, and 14 weeks of age.
Tritanrix, Hiberix, and Mencevax are trademarks of the
GlaxoSmithKline group of companies. Meningitec is a trade-
mark of Wyeth.
Half of the subjects in each of the five primary vaccination
groups were randomly selected to participate in a polysac-
charide challenge study at 10 months of age, where they
received 10 mg plain PRP and 10 mg of both MenA and MenC
polysaccharide vaccine (one fifth dose ofMencevaxTM AC). All
subjects received DTP booster vaccination during the second
year of life and the results of this DTP booster study will be
reported separately.
Vaccines
All vaccines were developed and manufactured by GlaxoS-
mithKline (GSK) Biologicals (Rixensart, Belgium), except
MeningitecTM, which was developed and manufactured by
Wyeth (Pearl River, NY, USA). The DTPw—HBV vaccine (Tri-
tanrixTM-HepB) was administered separately in the DTPw—
HBV + Hib group, or was used to reconstitute lyophilized Hib—
MenAC or HiberixTM vaccines in the DTPw—HBV/Hib—MenAC
and DTPw—HBV/Hib + MenC groups. The composition of Tri-
tanrixTM-HepB has been described elsewhere.17 The Hib—
MenAC component of the experimental heptavalent vaccines
comprised PRP, MenA (PSA), and MenC (PSC) capsular poly-
saccharides at the dosages described above, each conjugated
to tetanus toxoid (TT). The DTPw—HBV/Hib—MenAC 2.5/2.5
vaccine was prepared by injecting the full content of two
monodose vials of TritanrixTM-HepB vaccine into the vial
containing the lyophilized Hib—MenAC 5/5 vaccine and
removing a single dose (0.5 ml) of the mixed vaccines for
injection. HiberixTM contained 10 mg PRP conjugated to TT.
MencevaxTM AC contained 50 mg each of purified PSA and PSC.
MeningitecTM contained 10 mg PSC conjugated to Corynebac-
terium diphtheria CRM197 protein. All DTPw-containing vac-
cines were administered in the left thigh. All concomitant
vaccines (HiberixTM in the DTPw—HBV + Hib andMeningitecTM
in the DTPw—HBV/Hib + MenC groups) were administered in
the right thigh. Tritanrix, Hiberix, and Mencevax are trade-
marks of the GlaxoSmithKline group of companies. Meningi-
tec is a trademark of Wyeth.
Assessment of immunogenicity
Blood samples (3.5 ml) were collected before and one month
after the three-dose primary vaccination course, and prior to
and onemonth after the polysaccharide challenge. Sera were
stored at 20 8C until blinded analysis at GSK, Rixensart,
Belgium.
Bactericidal dilution titers against MenA and MenC (SBA-
MenA, SBA-MenC) were measured by a serum bactericidal
test using baby rabbit complement.18 The cut-off of the testwas a 1:8 dilution.19 Antibodies against PSA and PSC were
measured by ELISA with an assay cut-off of 0.3 mg/ml.20
Antibodies against PRP, diphtheria, and tetanus toxoids,
Bordetella pertussis antigens (BPT), and hepatitis B surface
antigen (HBs) were measured by ELISA. The cut-off values for
the assays were 0.15 mg/ml for anti-PRP, 0.1 IU/ml for
diphtheria and tetanus toxoid antibodies, 15 ELISA units/
ml (EL.U/ml) for BPT, and 10 mIU/ml for anti-HBs. Subjects
with a post-primary anti-diphtheria antibody concentra-
tion < 0.1 IU/ml by ELISA were retested using an in vitro
neutralization assay on Vero cells. The cut-off of the Vero-
cell assay was 0.016 IU/ml.
Serum bactericidal titers 1:8 against MenA or MenC, or
antibody concentrations against PRP, tetanus, diphtheria, or
HBs equal to or greater than the assay cut-off (by ELISA or the
in vitro neutralization assay for diphtheria antibodies) were
considered to be protective. For pertussis, a vaccine
response was defined in initially seronegative subjects as a
post-vaccination antibody concentration equal to, or above
the assay cut-off value. In initially seropositive subjects, a
pertussis vaccine response was defined as a post-vaccination
concentration equal to or greater than the individual’s pre-
vaccination titer (thereby taking into account the half-life of
maternal antibodies).
Assessment of safety
Solicited local symptoms of pain, redness, and swelling at the
injection site, and general symptoms of fever (defined as
axillary body temperature 37.5 8C), irritability/fussiness,
drowsiness, and loss of appetite were recorded by the par-
ents/guardians on the day of each vaccination and for seven
subsequent days on diary cards provided by the sponsor. All
adverse events occurring within one month (minimum 30
days) following administration of each vaccine dose were
recorded. Serious adverse events (SAEs) were recorded from
enrolment in the primary phase until one month after the
booster dose in the second year of life.
The intensity of reported symptoms was scored on a three-
point scale. Grade 3 pain was defined as ‘cries when limb is
moved/spontaneously painful’, grade 3 redness and swelling
as diameter >30 mm, grade 3 fever as axillary body tem-
perature >39.5 8C, and for all other adverse events grade 3
intensity was defined as an event that would prevent normal
everyday activities and that would cause the parents/guar-
dians to seek medical advice. The parents/guardians were
asked to contact the investigator immediately if the child
manifested any signs that were perceived as serious.
Statistical methods
The main objectives of the studies were to evaluate the non-
inferiority of the DTPw—HBV/Hib—MenAC 2.5/2.5 vaccine
compared to DTPw—HBV + Hib with respect to the Hib
response and compared to DTPw—HBV/Hib + MenC for the
immunogenicity of the MenC antigen, to evaluate immuno-
genicity of the MenA antigen of the DTPw—HBV/Hib—MenAC
2.5/2.5 vaccine, to evaluate the persistence of antibodies
against Hib, MenA, and MenC at 10 months of age as well as
immune memory induced by the primary vaccination, and to
assess the safety and reactogenicity of the vaccines.
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primary vaccination and immune response analyses were
performed on the (primary and challenge) according-to-pro-
tocol (ATP) cohorts for immunogenicity and the persistence
analysis on the ATP cohort for antibody persistence, whereas
the safety analysis was performed on the primary total
vaccinated cohort.
The geometric mean antibody concentrations/titers
(GMCs or GMTs) with 95% confidence intervals (CIs) were
calculated for each antibody tested and for the serum bac-
tericidal assay at each time point, by taking the anti-log10 of
the mean of the log10 concentration/titer transformations.
Seropositivity/seroprotection/vaccine response rates were
calculated with exact 95% CIs.
Exploratory comparisons were performed through com-
putation of standardized asymptotic 95% CIs for the differ-
ence in seroprotection, seropositivity, and vaccine response
rates between each of the three Hib—MenAC formulations
and the relevant control group one month after the primary
vaccination. Additionally, 95% CIs for the GMC/T ratios
between each of the study vaccine groups and the control
group were calculated using a one-way ANOVA model on the
log10 transformation of the titers or concentrations using the
vaccine group as the only covariate. Two vaccine groups were
considered significantly different if the 95% CI for the dif-
ference in rates between the two vaccine groups did not
contain the value ‘0’, or if the 95% CI for the GMT/GMC ratioFigure 1 Number of subjects who participated in the primary vaccin
withdrawal or elimination from analyzed cohorts.between the two vaccine groups did not contain the value
‘1’. For the MenA response, in the absence of a comparator
group the lower limit of the exact 95% CI on the percentage
of subjects with SBA-MenA titer 1:8 was compared to 70%
for this first clinical study with a DTPw—HBV/Hib—MenAC
vaccine.
The incidence and intensity of each solicited adverse
event was tabulated with 95% CI. Serious adverse events
and dropouts due to adverse events were described.
Results
The study was conducted at a single center in Manila between
November 2002 and April 2004. There were 525 children
enrolled and 524 vaccinated in the primary vaccination phase
(Figure 1). A total of 217 subjects received the polysacchar-
ide challenge at 10 months of age.
Demographic characteristics
At enrolment the mean age of subjects was 7.1 weeks
(standard deviation (SD) 1.2 and range 6—10 weeks), 48.7%
of subjects were female, and all were of Asian origin. Mean
weight was 4.6 kg (SD 0.7) and the mean length of subjects
was 56.1 cm (SD 2.4). Demographic characteristics between
groups were similar (data not shown). The mean age ofation and plain polysaccharide challenge studies, and reasons for
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Table 1 SBA-MenA, SBA-MenC, anti-PSA, anti-PSC, and anti-PRP antibody responses after primary vaccination (ATP cohort for
immunogenicity)
Group DTPw—HBV/
Hib—MenAC 2.5/2.5
(N = 103)
DTPw—HBV/
Hib—MenAC 2.5/5
(N = 104)
DTPw—HBV/
Hib—MenAC 5/5
(N = 105)
DTPw—HBV + Hib
(N = 103)
DTPw—HBV/
Hib + MenC
(N = 104)
SBA MenA
1:8 97.7 (91.9; 99.7) 100 (95.8; 100) 100 (96.2; 100) 6.8 (2.5; 14.3) 9.1 (4.0; 17.1)
GMT 316.7 (251.4; 398.9) 418.5 (358.6; 488.5) 363 (310.5; 424.4) 5.6 (4.3; 7.4) 5.6 (4.4; 7.2)
SBA MenC
1:8 99.0 (94.7; 100) 100 (96.5; 100) 100 (96.5; 100) 2.9 (0.6; 8.4) 100 (96.5; 100)
GMT 3132.6 (2496.9; 3930.1)b 4205.7 (3408.6; 5189.2) 3697.6 (3118.2; 4384.6) 4.7 (3.9; 5.6) 4500.9 (3903.8; 5189.4)b
Anti-PSA (mg/ml)
2 100 (96.4; 100) 100 (96.5; 100) 99.0 (94.8; 100) 0.0 (0.0; 3.6) 1.0 (0.0; 5.4)
GMC 18.1 (15.3; 21.3) 26.5 (22.8; 30.8) 23.4 (20.0; 27.3) 0.15 (0.15; 0.15) 0.17 (0.15; 0.18)
Anti-PSC (mg/ml)
2 100 (96.5; 100) 100 (96.4; 100) 100 (96.5; 100) 1.0 (0.0; 5.6) 100 (96.5; 100)
GMC 49.0 (43.2; 55.6) 71.1 (62.5; 80.9)b 61.6 (54.9; 69.2) 0.17 (0.15; 0.19) 58.0 (51.4; 65.5)
Anti-PRP (mg/ml)
0.15 100 (96.5; 100) 99.0 (94.8; 100) 100 (96.5; 100) 100 (96.5; 100) 100 (96.5; 100)
1 96.1 (90.4; 98.9) 98.1 (93.2; 99.8) 99.0 (94.8; 100) 99.0 (94.7; 100) 95.2 (89.1; 98.4)
GMC 20.8 (16.0; 27.1)a,b 22.6 (17.7; 28.9)a, b 19.4 (15.3; 24.5)a, b 38.5 (29.9; 49.6)b 10.9 (8.6; 13.9)
Results are % (95% CI) or GMC/T (95% CI). N, number of subjects with available results; %, percentage of subjects with antibody
concentrations above the specified cut-off.
DTPw, diphtheria—tetanus—whole cell pertussis; HBV, hepatitis B virus; Hib, Haemophilus influenzae type b; Men, meningitis; CI, confidence
interval; SBA, serum bactericidal antibody; PSA, MenA capsular polysaccharide; PSC, MenC capsular polysaccharide; PRP, polyribosylribitol
phosphate; ATP, according-to-protocol; GMT, geometric mean titer; GMC, geometric mean concentration.
a Statistically significantdifferencecompared to theDTPw—HBV + Hib control group (95%CI in termsofGMTs/GMCs ratio doesnot include ‘1’).
b Statistically significant difference compared to the DTPw—HBV/Hib + MenC control group (95% CI in terms of GMTs/GMCs ratio does not
include ‘1’).subjects at the time of the polysaccharide challenge was 43.9
weeks (SD 1.4).
Immunogenicity: MenA response
After primary vaccination with one of the three experimental
heptavalent vaccines, the percentage of subjects with SBA-
MenA titers 1:8 was at least 97.7%, compared to less than
10% of subjects in the two control groups (Table 1). The lower
limit of the 95% CI for the percentage of subjects with SBA-
MenA titers1:8 was over 90% in the DTPw—HBV/Hib—MenAC
groups, well above the pre-defined clinical limit of 70%. At
least 99% of subjects in the DTPw—HBV/Hib—MenAC groups
achieved anti-PSA antibody concentrations 2 mg/ml, with
markedly higher GMCs in each group compared to the con-
trols.
Prior to the polysaccharide challenge at 10 months of age,
seroprotective SBA-MenA titers continued to be observed in
at least 85.7% of DTPw—HBV/Hib—MenAC recipients, and had
developed in 69.4% to 80.5% of control subjects (Table 2).
Anti-PSA seropositivity rates and antibody GMCs continued to
be significantly higher in the DTPw—HBV/Hib—MenAC primed
groups (Tables 2 and 3).
A dose of plain MenA polysaccharide induced a rise in SBA-
MenA titers in all groups (Table 3), with higher point esti-
mates in the MenA-primed groups. At least 96.7% of subjects
primed with a DTPw—HBV/Hib—MenAC vaccine reached
titers 1:8 (Table 2). Significantly higher-fold increases inanti-PSA antibodies were observed in the DTPw—HBV/Hib—
MenAC groups compared to controls.
Immunogenicity: MenC response
At least 99.0% of subjects had seroprotective SBA-MenC titers
and were seropositive for anti-PSC antibodies after primary
vaccination with each of the experimental DTPw—HBV/Hib—
MenAC vaccines, with no difference compared to the MenC
control vaccine. A statistically significant lower SBA-MenC
GMTwas observed in group 2.5/2.5, as well as a statistically
significant higher anti-PSC GMC in group 2.5/5 when com-
pared to the MenC control vaccine.
At 10 months of age, 91.3% to 94.9% of subjects primed
with DTPw—HBV/Hib—MenAC continued to have seroprotec-
tive SBA-MenC titers, compared to 97.8% in the DTPw—HBV/
Hib + MenC control group, and 7.3% in the DTPw—HBV + Hib
control group (Table 2). Immune memory was demonstrated
by a marked response to the polysaccharide C challenge in
terms of SBA-MenC GMTs and anti-PSC antibody GMCs in all
MenC primed groups, compared to a minimal response in
subjects who received primary vaccination with DTPw—
HBV + Hib (Tables 2 and 3).
Immunogenicity: PRP response
Following primary vaccination, more than 99.0% of subjects
in all groups achieved an anti-PRP antibody concentration
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Table 3 SBA and antibody GMC/GMT to polysaccharide challenge at 10 months of age (ATP cohort for antibody persistence for pre-polysaccharide challenge or challenge ATP cohort
for immunogenicity for post-polysaccharide challenge)
Group Time-point MenA MenC PRP
SBA PSA SBA PSC
N GMT (95% CI) N GMC (mg/ml) (95% CI) N GMT (95% CI) N GMC (mg/ml) (95% CI) N GMC (mg/ml) (95% CI)
DTPw—HBV/Hib—MenAC 2.5/2.5 Pre-PS 39 164.6 (99.7; 271.7) 44 1.78 (1.24; 2.55) 46 335.1 (206.6; 543.4) 44 7.16 (5.83; 8.78) 44 7.15 (4.62; 11.07)
Post-PS 32 767.1 (606.3; 970.6) 45 24.66 (17.73; 34.29) 45 2722.4 (1950.6; 3799.6) 43 21.91 (17.76; 27.03) 45 68.49 (41.29; 113.61)
DTPw—HBV/Hib—MenAC 2.5/5 Pre-PS 35 142.1 (81.9; 246.6) 36 1.49 (1.05; 2.13) 39 406.9 (254.2; 651.2) 36 7.99 (6.38; 10.01) 36 3.64 (2.35; 5.62)
Post-PS 30 923.3 (711.6; 1196.0) 39 23.42 (16.68; 32.87) 38 2718.0 (1959.4; 3770.4) 38 23.76 (18.46; 30.58) 39 44.22 (26.37; 74.14)
DTPw—HBV/Hib—MenAC 5/5 Pre-PS 37 202.8 (134.9; 304.9) 41 2.11 (1.48; 3.00) 39 389.1 (235.6; 642.5) 41 7.78 (6.34; 9.54) 41 4.69 (3.10; 7.08)
Post-PS 30 682.4 (451.4; 1031.7) 39 23.06 (16.52; 32.19) 39 2243.2 (1536.6; 3274.7) 35 21.61 (17.70; 26.38) 39 48.77 (31.24; 76.14)
DTPw—HBV + Hib Pre-PS 36 84.1 (40.6; 174.3) 42 0.16 (0.15; 0.17) 41 4.8 (3.7; 6.2) 42 0.16 (0.14; 0.17) 42 6.14 (3.99; 9.44)
Post-PS 39 511.1 (353.3; 739.3) 38 0.88 (0.49; 1.56) 40 11.1 (5.7; 21.9) 42 7.88 (5.86; 10.59) 42 41.80 (25.67; 68.05)
DTPw—HBV/Hib + MenC Pre-PS 41 127.2 (70.5; 229.7) 45 0.16 (0.15; 0.18) 45 397.4 (266.5; 592.7) 45 7.78 (6.04; 10.02) 45 4.14 (2.74; 6.26)
Post-PS 44 538.5 (367.3; 789.4) 45 0.74 (0.46; 1.20) 45 1416.6 (927.3; 2164.2) 44 16.54 (12.91; 21.18) 45 22.29 (13.83; 35.91)
N, number of subjects with available results.
DTPw, diphtheria—tetanus—whole cell pertussis; HBV, hepatitis B virus; Hib, Haemophilus influenzae type b; Men, meningitis; CI, confidence interval; Pre-PS, pre-polysaccharide challenge; post-PS, post-polysaccharide challenge; SBA, serum bactericidal
antibody; PSA, MenA capsular polysaccharide; PSC, MenC capsular polysaccharide; PRP, polyribosylribitol phosphate; ATP, according-to-protocol; GMT, geometric mean titer; GMC, geometric mean concentration.
Table 2 SBA and antibody responses to polysaccharide challenge at 10 months of age (ATP cohort for antibody persistence for pre-polysaccharide challenge or challenge ATP cohort
for immunogenicity for post-polysaccharide challenge)
Group DTPw—HBV/Hib—MenAC 2.5/2.5 DTPw—HBV/Hib—MenAC 2.5/5 DTPw—HBV/Hib—MenAC 5/5 DTPw—HBV + Hib DTPw—HBV/Hib + MenC
Pre-PS Post-PS Pre-PS Post-PS Pre-PS Post-PS Pre-PS Post-PS Pre-PS Post-PS
N % (95% CI) N % (95% CI) N % (95% CI) N % (95% CI) N % (95% CI) N % (95% CI) N % (95% CI) N % (95% CI) N % (95% CI) N % (95% CI)
SBA MenA
1:8 39 92.3 (79.1; 98.4) 32 100 (89.1; 100) 35 85.7 (69.7; 95.2) 30 100 (88.4; 100) 37 94.6 (81.8; 99.3) 30 96.7 (82.8; 99.9) 36 69.4 (51.9; 83.7) 39 97.4 (86.5; 99.9) 41 80.5 (65.1; 91.2) 44 95.5 (84.5; 99.4)
1:128 39 69.2 (52.4; 84.0) 32 100 (89.1; 100) 35 74.3 (56.7; 87.5) 30 100 (88.4; 100) 37 78.4 (61.8; 90.2) 30 96.7 (82.8; 99.9) 36 61.1 (43.5; 76.9) 39 97.4 (86.5; 99.9) 41 73.2 (57.1; 85.8) 44 93.2 (81.3; 98.6)
SBA MenC
1:8 46 91.3 (79.2; 97.6) 45 100 (92.1; 100) 39 94.9 (82.7; 99.4) 38 100 (90.7; 100) 39 94.9 (82.7; 99.4) 39 100 (91.0; 100) 41 7.3 (1.5; 19.9) 40 20.0 (9.1; 35.6) 45 97.8 (88.2; 99.9) 45 97.8 (88.2; 99.9)
1:128 46 84.8 (71.7; 93.7) 45 97.8 (88.2; 99.9) 39 84.8 (69.5; 92.5) 38 100 (90.7; 100) 39 82.1 (66.5; 92.5) 39 100 (91.0; 100) 41 2.4 (0.1; 12.9) 40 20.0 (9.1; 35.6) 45 82.2 (67.9; 92.0) 45 95.6 (84.9; 99.5)
Anti-PSA (mg/ml)
0.3 44 93.2 (81.3; 98.6) 45 100 (92.1; 100) 36 94.4 (81.3; 99.3) 39 100 (91.0; 100) 41 95.1 (83.5; 99.4) 39 100 (91.0; 100) 42 4.8 (0.6; 16.2) 38 71.1 (54.1; 84.6) 45 6.7 (1.4; 18.3) 45 62.2 (46.5; 76.2)
2 44 50.0 (34.6; 65.4) 45 100 (92.1; 100) 36 30.6 (16.3; 48.1) 39 97.4 (86.5; 99.9) 41 61.0 (44.5:75.8) 39 97.4 (86.5; 99.9) 42 0.0 (0.0; 8.4) 38 31.6 (17.5; 48.7) 45 0.0 (0.0; 7.9) 45 24.4 (12.9; 39.5)
Anti-PSC (mg/ml)
0.3 44 100 (92.0; 100) 43 100 (91.8; 100) 36 100 (90.3; 100) 38 100 (90.7; 100) 41 100 (91.4; 100) 35 100 (90.0; 100) 42 2.4 (0.1; 12.6) 42 100 (91.6; 100) 45 100 (92.1; 100) 44 100 (92.0; 100)
2 44 95.5 (84.5; 99.4) 43 100 (91.8; 100) 36 97.2 (85.5; 99.9) 38 100 (90.7; 100) 41 100 (91.4; 100) 35 100 (90.0; 100) 42 0.0 (0.0; 8.4) 42 92.9 (80.5; 98.5) 97.8 (88.2; 99.9) 44 100 (92.0; 100)
Anti-PRP (mg/ml)
0.15 44 97.7 (88.0; 99.9) 45 100 (92.1; 100) 36 100 (90.3; 100) 39 100 (91.0; 100) 41 95.1 (83.5; 99.4) 39 100 (91.0; 100) 42 100 (91.6; 100) 42 100 (91.6; 100) 45 100 (92.1; 100) 45 100 (92.1; 100)
1 44 88.6 (75.4; 96.2) 45 97.8 (88.2; 99.9) 36 75.0 (57.8; 87.9) 39 100 (91.0; 100) 41 90.2 (76.9; 97.3) 39 100 (91.0; 100) 38 90.5 (77.4; 97.3) 42 97.6 (87.4; 99.9) 45 82.2 (67.9; 92.0) 45 95.6 (84.9; 99.5)
DTPw, diphtheria—tetanus—whole cell pertussis; HBV, hepatitis B virus; Hib, Haemophilus influenzae type b; Men, meningitis; CI, confidence interval; Pre-PS, pre-polysaccharide challenge; post-PS, post-polysaccharide challenge; SBA, serum bactericidal
antibody; PSA, MenA capsular polysaccharide; PSC, MenC capsular polysaccharide; PRP, polyribosylribitol phosphate; ATP, according-to-protocol.
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.0.15 mg/ml and at least 95.2% had concentrations1.0 mg/
ml (Table 1). Anti-PRP antibody GMCs elicited by the DTPw—
HBV/Hib—MenAC formulations were significantly higher than
those induced in the DTPw—HBV/Hib + MenC control group,
but significantly lower than those observed in the group
receiving monovalent Hib (group DTPw—HBV + Hib). There
were no differences observed between the experimental
vaccines and the control groups in terms of each cut-off.
Prior to the polysaccharide challenge, at least 95.1% of
subjects who received an experimental DTPw—HBV/Hib—
MenAC vaccine continued to have anti-PRP antibody concen-
trations 0.15 mg/ml (Table 2). The plain PRP challenge
induced marked rises in anti-PRP antibody concentrations
in all groups, reaching higher values in group 2.5/2.5 and the
lowest values in group DTPw—HBV/Hib + MenC (Table 3).
Immunogenicity: response to the DTPw—HBV
vaccine antigens
One month after the primary vaccination course, anti-
diphtheria, anti-tetanus, and anti-HBs seroprotection rates
of all Hib—MenAC groups were similar to those in the DTPw—
HBV + Hib control group (Table 4). The anti-diphtheria ser-
oprotection level was highest in the DTPw—HBV/Hib + MenC
control group. The 5/5 group had a significantly lower anti-
BPT vaccine response rate compared to the DTPw—HBV + Hib
group.
Anti-diphtheria antibody concentrations were signifi-
cantly higher in the DTPw—HBV/Hib + MenC group compared
to the DTPw—HBV/Hib—MenAC and the DTPw—HBV + Hib
groups, whereas anti-tetanus antibody GMCs were signifi-
cantly higher in each of the DTPw—HBV/Hib—MenAC groups
compared to both control groups. Compared to the DTPw—
HBV + Hib group, both Hib—MenAC formulations with 5 mg of
PSA and PSC showed lower anti-BPTantibody concentrations,
and the Hib—MenAC formulation containing 5 mg of Hib, PSA,
and PSC also had a lower anti-HBs-antibody GMC (Table 4).
Safety
The incidence of solicited local or general symptoms that
occurred after primary vaccination was in the same range
across the five groups (Figure 2). Pain was the most fre-
quently reported local symptom after primary vaccination,
and irritability and fever (axillary temperature37.5 8C) the
most frequently reported systemic symptoms in all groups.
Overall, grade 3 symptoms were reported in 16.8—22.9% of
doses. Specifically, in each group, fever >39.5 8C (axillary)
was reported after a maximum of 1% of all doses.
Seven SAEs were reported during the primary vaccination
phase of the study. One case was fatal: a child developed
meningitis and sepsis (no organism isolated) 23 days after the
third dose of DTPw—HBV + Hib.
During the period between the end of the primary vacci-
nation phase and the plain polysaccharide challenge at 10
months of age, 11 SAEs occurred in the study population of
which three were fatal: one subject died of pneumonia that
commenced 78 days after the third dose of DTPw—HBV/
Hib + MenC, one died of pneumonia more than one month
after the third dose of 2.5/5 (no further details available),
and one died due to a cardiac arrest during an episode of
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Figure 2 Solicited local and general symptoms after primary vaccination (all doses, total vaccinated cohort).acute gastroenteritis that began 4 months after the third
dose of DTPw—HBV + Hib.
Six non-fatal SAEs were reported after the administration
of the polysaccharide challenge, of which one (acute gastro-
enteritis) occurred during the 31 days following the poly-
saccharide challenge. None of the SAEs were considered by
the investigator to be related to vaccination.Discussion
This study has demonstrated the feasibility of a combined,
heptavalent vaccine comprising recommended EPI antigens
for infant vaccination (diphtheria, tetanus, pertussis, hepa-
titis B) and conjugate polysaccharide components against Hib
and meningococcal serogroup A and C diseases, for the
primary vaccination of infants.
Three formulations of the experimental DTPw—HBV/Hib—
MenAC vaccine were evaluated, and the study assessed the
optimum dose of conjugated polysaccharide required to
induce a satisfactory immune response to Hib, MenC, and
MenA. The formulation with the lowest dose of conjugated
PRP, MenA, and MenC polysaccharides (group 2.5/2.5) suc-
cessfully primed against MenA and MenC when given as a
three-dose primary vaccination course in infancy, while
immune responses to Hib, diphtheria, tetanus, pertussis,
and hepatitis B were similar to those observed after vaccina-
tion with DTPw—HBV + Hib. Both formulations with higher
dosage of Hib—MenAC induced lower hepatitis B and pertussis
antibody concentrations compared to the control group. The
reason for this is unclear and may warrant further investiga-
tion.
For PRP there is evidence that a lower amount of PRP than
that found in monovalent Hib-conjugate preparations is suf-ficient to induce an equivalent immune response.21—28 It was
anticipated that for MenA and MenC conjugates, less than
10 mg of polysaccharide would be sufficient to induce an
acceptable immune response, as was previously observed
during the development of conjugated MenC vaccines28,29
and combined meningococcal vaccines including MenA con-
jugates30; this was confirmed in the present study. Indeed the
formulation with the lowest dose (2.5/2.5 group) elicited
high and persistent seropositivity rates for the three Hib,
MenA, and MenC antigens with a robust anamnestic response
to the polysaccharide challenge doses.
Of note, the lowest anti-PRP antibody GMC was observed
in the control group where Hib was given combined with
DTPw—HepB and co-administered with the MenC conjugate
vaccine (conjugated to CRM197), although seroprotection
levels remained high. Interestingly, all of the DTPw—HBV/
Hib—MenAC combinations (with MenC conjugated to TT)
induced higher anti-PRP GMCs. Several factors might have
impacted on the Hib responses in the different groups, such
asmixed or separate administration of the Hib conjugate, the
combination with other TT-conjugates in the Hib—MenAC
groups, or a negative impact of the concomitant administra-
tion of the MenC-CRM197 with the whole-cell pertussis com-
bination vaccine.
The first clinical trials of conjugate MenA vaccines were
reported during the 1990s.31 Since then, a conjugate tetra-
valent vaccine containing 4 mg PSA (MenactraTM, Sanofi Pas-
teur) has been licensed for use in adolescents and adults in
the USA, but not in infants in whom it is only modestly
immunogenic.30 Immune memory following MenA conjugate
vaccination has been demonstrated for other experimental
vaccines, although an experimental vaccine tested in both
the UK32 and the Gambia33 was shown to induce immune
memory in the first country and not in the latter.
286 S. Gatchalian et al.Natural immunity against prevalent meningococcal strains
is known, but it has also been observed in countries where
MenA is considered not to circulate, indicating cross-reaction
with other bacterial antigens. Serum bactericidal activity is
known to steadily increase through childhood to 50—80% by
12 years of age.34 There is little information on the epide-
miology of meningococcal disease in the Philippines but the
presence of endemic MenA disease or cross-reacting bacteria
contributing to the development of immunity over time
cannot be ruled out. At the time the study was conducted,
a MenA outbreak was under investigation in Baguio located
246 kilometers from Manila.11
It was not possible to conclude on the immune memory
based on results of the serum bactericidal assays due to
rapidly developing natural immunity measured by our bac-
tericidal assay in Filipino children. In this setting, anti-PSA
ELISA measurement may not be the most appropriate method
to assess immune memory. Alternatively, other MenA strains
than the strain used in our SBA assay (F8238 of L11 immu-
notype) may be used as this may better discriminate between
vaccine-induced protective immunity and cross-reacting nat-
ural immunity.35
Whether a booster dose of conjugate meningococcal
vaccine is required during the second year of life has been
a matter for debate. In the UK, primary vaccination is given
in an early (2 months of age) and rapid (one month intervals
between doses) schedule without a booster. Waning immu-
nity and reduced vaccine effectiveness of Hib36 and MenC37
vaccines has been observed in the years following primary
vaccination in UK infants, strongly suggesting the need for a
booster dose in the second year of life. A booster dose of
MenA conjugate vaccine may also be required, since at
present there is no reason to suspect that the immune
response to MenA will behave differently to Hib and MenC.
The most appropriate timing for the booster dose, as well as
the total number of vaccine doses minimally needed to
induce long-term protection warrants further investigation.
In this study no increase in reactogenicity of the DTPw—
HBV/Hib—MenAC vaccines during the primary vaccination
course was observed when compared with the licensed
DTPw—HBV + Hib vaccines.
The control of meningococcal disease due to serogroup A
poses particular challenges. Group A N. meningitidis is
responsible for epidemics in developing regions that cause
numerous deaths. From seroprevalence studies in Sudan,38 it
is estimated that>80% herd immunity is necessary to prevent
epidemics.38,39
Currently the WHO recommends commencement of mass
vaccination against meningitis with the onset of epidemics.
The success of this reactive approach depends on early
recognition of an impending epidemic and efficient logistics
in place to ensure rapid vaccine delivery. During the
MenA epidemic in Sudan during 1998 and 1999, more than
33 000 cases and 2386 deaths occurred, despite vaccination
of one-third of the population.38 It is clear that reactive
vaccination policies can only be of limited success compared
to preventive immunization that could have a significant
impact on meningitis outbreak diffusion.40 Routine vaccina-
tion against MenA and MenC is the only way to provide lasting,
widespread protection of the population against disease.
Combining the Hib, MenC, and MenA vaccine components
with the established DTPw—HBV vaccine in a single injectionis the simplest means to ensure acceptance, rapid uptake,
and high coverage.
The new heptavalent DTPw—HBV/Hib—MenAC vaccine
delivers five of the currently recommended EPI antigens,
as well as MenA and MenC conjugate vaccines. This hepta-
valent vaccine for routine infant vaccination offers the pos-
sibility to reduce deaths and long-term sequelae associated
with endemic and epidemic meningococcal disease.
Conclusions
This study shows the feasibility of a novel heptavalent
DTPw—HBV/Hib—MenAC vaccine for the primary vaccination
of infants. The formulation of this novel vaccine with the
lowest dose of conjugated PRP, Men A, and MenC polysac-
charides (2.5 mg of each) was well tolerated, immunogenic,
had good persistence of antibodies, and demonstrated
immune memory, and consequently was selected for further
development.
Further investigation is needed to provide information on
the tolerability and immunogenicity of a booster dose, as
well as the persistence of meningococcal bactericidal anti-
bodies over time, in order to determine the total number of
vaccine doses needed to induce long-term protection.
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